This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EBV-nRNA

Lakewood-Amedex, Inc.

Drug Names(s): EBVnRNA, nanoRNA cancer therapy

Description: The nRNA technology platform is essentially antisense siRNA gene silencing. The company's proprietary chemistry allows the production of a chirally pure RNA that is proposed to result in more efficient targeting/silencing with less toxicity.The nRNAs are also proposed to be more stable and allow for more routes of administration.

The direct gene target for EBV-nRNA has not been specified, but we assume it to target a gene of the Epstein-Barr Virus.


EBV-nRNA News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug